|本期目录/Table of Contents|

[1]黄彩英,陈 萍,潘 杰,等.紫杉醇治疗胸腺鳞癌致大疱性表皮松解坏死性药疹救治成功一例[J].中华肺部疾病杂志,2023,(03):442-444.[doi:10.3877/cma.j.issn.1674-6902.2023.03.041 ]
点击复制

紫杉醇治疗胸腺鳞癌致大疱性表皮松解坏死性药疹救治成功一例(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年03期
页码:
442-444
栏目:
病例报告
出版日期:
2023-06-20

文章信息/Info

Title:
-
作者:
黄彩英; 陈 萍; 潘 杰; 莫彩云; 尚敏红; 周 俊
400037 重庆,陆军(第三)军医大学第二附属医院肿瘤科
Author(s):
-
关键词:
胸腺鳞癌;  紫杉醇;  大疱性表皮松解;  药疹
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.03.041
摘要:
-
Abstract:
-

参考文献/References:

1 Marx A, Chan JKC, Coindre JM, et al. The 2015 World Health Organization classification of tumors of the thymus continuity and changes[J]. J Thorac Oncol, 2015, 10(10): 1383-1395.
2 Scorsetti M, Leo F, Trama A, et al. Thymoma and thymie carcinomas[J]. Crit Rev Oncol Hematol, 2016, 99: 332-350.
3 中国临床肿瘤学会. 常见恶性肿瘤诊疗指南(2021)下册[M]. 北京: 人民卫生出版社, 2021: 89-90.
4 赵 意. 注射用紫杉醇(白蛋白结合型)的临床药物不良反应观察[J]. 中国实用医药, 2021, 16(15): 137-139.
5 王郁薇, 蒙 龙, 刘 箫. 基于美国FDA不良事件数据库的注射用紫杉醇(白蛋白结合型)不良反应信号挖掘[J]. 中国药房, 2021, 32(3): 328-333.
6 周香珍, 李京泰, 任少琳, 等. 盐酸多柔比星脂质体注射液联合注射用紫杉醇(白蛋白结合型)致严重皮肤损害1例分析[J]. 中国药物警戒, 2021, 18(3): 280-283.
7 Zeng J, Yin J, Yuan D, et al. Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer[J]. Clin Respir J, 2017, 11(5): 632-639.
8 Stern RS, Divito SJ. Stevens-Johnson syndrome and toxic epidernal necrolysis: Associations, outcomes, and pathobiology thirty years of progress but still much to be done[J]. J Invest Dermatol, 2017, 137: 1004.
9 Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs[J]. N Engl J Med, 1994, 331: 1272.
10 Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK[J]. J Invest Dernatol, 2017, 137: 1240.
11 Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: A nationwidel population-based study using national health insurance database in Korea[J]. PLos One, 2016, 11: e0165933.
12 Lois LG, Lauren L, Joyce W, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors[J]. Drug Saf, 2005, 28(10): 917-924.
13 Jean CR, Judith PK, Luigi N, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis[J]. N Engl J Med, 1995, 333(24): 1600-1607.
14 Caria FP, Vicente GP. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children[J]. Arch Dis Child, 2013, 98(12): 998-1003.
15 Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with enphasis on recently marketed drugs. The EuroSCAR-study[J]. J Invest Dermatol, 2008, 128: 35.
16 Gravante G, Delogu D, Marianetti M, et al. Toxic epidernal necrolysis and Steven-Johnson syndrone in oncologic patients[J]. Eur Rev Med Pharmacol Sci, 2007, 11: 269.
17 Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology[J]. Anticancer Drugs, 2014, 25: 225.
18 Sonmers KR, Kong KM, Bui DT, et al. Stevens-Johnson syndrone/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine[J]. Anticancer Drugs, 2003, 14: 659.
19 Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Am J Clin Dermatol, 2000, 1: 349.
20 Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis[J]. Clin Pharnacol Ther, 2010, 88: 60.
21 Creamer D. Walsh SA. Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidernall necrolysis in adults 2016[J]. Br J Dermatol, 2016, 174: 1194.
22 Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115: 149.
23 Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States[J]. Arch Dermatol, 2004, 140: 890.
23 Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Perfornance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis[J]. J Invest Dermatol, 2006, 126: 272.
24 Ying S, Ho W, Chan HH. Toxic epidernal necrolysis: 10 years experience of a burns centre in Hong Kong[J]. Burns, 2001, 27: 372.
25 Atiyeh BS, Dhan R, Yassin MF, et al. Treatment of toxic epidernal necrolysis with noisture-retentive ointnent: a case report and review of the literature[J]. Dermatol Surg, 2003, 29: 185.
26 Boorboor P, Vogt PM, Bechara FG, et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain,improves mobilisation and decreases infection in elderly patients[J]. Burns, 2008, 34: 487.
27 蒋 瑶, 孟玉倩.中毒性大疱表皮坏死松解型药疹患儿行简易创面负压封闭引流的护理[J]. 中华急危重症护理杂志, 2020, 1(6): 558-561.
28 陈 伟, 王燕婷, 王宇等. 紫杉类抗肿瘤药物药学服务中国专家共识[J]. 中国医院用药评价与分析, 2022, 22(12): 1409-1427.
29 Yoneshima Y, Morita S, Ando M, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC[J]. J Thorac Oncol, 2021, 16(9): 1523-1532.
30 Srikala S Sridhar, Normand Blais, Ben Tran, et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer:the Canadian cancer trials group BL.12 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): 1751-1758.

备注/Memo

备注/Memo:
通信作者: 陈 萍, Email: 2549789472@qq.com
更新日期/Last Update: 2023-06-20